News | Patient Positioning Radiation Therapy | June 28, 2017

Augmenix Announces First New Zealand Prostate Cancer Patient Treated with SpaceOAR Hydrogel

Kathleen Kilgour Centre is the first cancer center in New Zealand to offer absorbable spacer designed to separate the rectum and the prostate during radiation treatment

Augmenix Announces First New Zealand Prostate Cancer Patient Treated with SpaceOAR Hydrogel

June 28, 2017 — Augmenix Inc. announced that the first patient in New Zealand has been treated with SpaceOAR hydrogel at the Kathleen Kilgour Centre (KKC) in Tauranga. SpaceOAR hydrogel is the first absorbable spacer designed to separate the rectum and prostate to reduce the risk of long-term side effects after radiation treatment.

Unintended injury to surrounding tissue during radiation therapy can lead to bowel, urinary and sexual symptoms that can affect patient health and quality of life (QOL). With SpaceOAR hydrogel, physicians can help reduce this risk by placing a hydrogel barrier to separate the prostate from adjacent healthy tissue. SpaceOAR hydrogel is initially implanted as a liquid that solidifies into a soft hydrogel that pushes the prostate and rectum apart. It remains stable for three months during radiation therapy and then is gradually absorbed and eliminated by the body.

In January 2017, Augmenix announced three-year post-treatment data from a prospective, randomized, multi-center, patient-blinded clinical trial showing that patients treated with SpaceOAR hydrogel prior to prostate cancer radiotherapy demonstrated significant rectal (bowel), urinary and sexual benefit through three years of follow up. During radiotherapy, the spacer resulted in a 73.5 percent reduction in rectal V70 radiation dose and a 49 percent reduction in median penile bulb radiation dose in patients treated with SpaceOAR hydrogel compared to men who did not receive the hydrogel (control). Overall patient wellness at three years was assessed by looking at the percent of patients with clinically significant declines in bowel, urinary and sexual QOL domains combined. Three years after radiotherapy, patients that were not treated with SpaceOAR hydrogel were 8 times more likely to experience significant declines in all three QOL areas (p=0.002). Among men who were sexually potent at baseline, the analysis showed that men in the SpaceOAR hydrogel arm were better able to maintain erections sufficient for intercourse through 3 years of follow-up (p=0.03). Of these men, 66.7 percent were able to achieve erections sufficient for intercourse at three years compared to 37.5 percent in the control arm, a 77.8 percent relative improvement.

“KKC is dedicated to providing the best care for our patients and the introduction of SpaceOAR hydrogel for men with prostate cancer is yet another step in achieving this,” said Leanne Tyrie, MBChB, genitourinary radiation oncologist and clinical director at the Kathleen Kilgour Centre. “The significant decrease in bowel, urinary and sexual side effects following radiotherapy when SpaceOAR hydrogel is utilised, made our decision to incorporate it as part of standard of care for prostate cancer patients very easy.”

SpaceOAR hydrogel is U.S. Food and Drug Administration (FDA)-cleared and CE marked.

For more information: www.augmenix.com

Related Content

Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s
High-intensity focused ultrasound (HIFU), a technology used to treat localized prostate cancer, has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology, Official Journal of the American Urological Association

Getty Images

News | Prostate Cancer | September 08, 2020
September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the h
the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
Single-dose radiotherapy replaces need for extra hospital visits, with benefits for patient safety and well-being

Getty Images

News | Women's Health | August 20, 2020
August 20, 2020— For most women with early breast cancer
A special issue of the Journal of Medical Imaging and Radiation Sciences features stories about the interpersonal skills beyond the technical aspects to care for and guide patients through medical imaging and radiation therapy procedures

Image courtesy of Canon

News | Patient Engagement | August 11, 2020
August 11, 2020 — "I went into the MRI
Global radiotherapy market revenue is set to expand from $7,222.4 million in 2019 to $17,194.4 million by 2030, at an 8.4% CAGR between 2020 and 2030, the key factor driving the market growth is the increasing number of cancer cases, according to the report published by P&S Intelligence.

Image courtesy of Elekta

News | Radiation Therapy | August 06, 2020
August 6, 2020 — Global ...
Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy.

Getty Images

News | Radiology Business | August 03, 2020
August 3, 2020 — Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly wel
JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...